Sanofi (NASDAQ:SNY – Get Rating) – Research analysts at Jefferies Financial Group dropped their Q4 2022 earnings per share estimates for Sanofi in a report issued on Thursday, July 7th. Jefferies Financial Group analyst P. Welford now anticipates that the company will post earnings per share of $0.94 for the quarter, down from their prior estimate of $1.00. The consensus estimate for Sanofi’s current full-year earnings is $4.13 per share.
Sanofi (NASDAQ:SNY – Get Rating) last posted its quarterly earnings results on Thursday, April 28th. The company reported $1.09 EPS for the quarter, topping analysts’ consensus estimates of $0.94 by $0.15. Sanofi had a return on equity of 25.34% and a net margin of 17.15%. The business had revenue of $10.85 billion during the quarter, compared to analysts’ expectations of $10.33 billion.
SNY has been the subject of several other reports. Barclays raised their price objective on shares of Sanofi from €90.00 ($93.75) to €105.00 ($109.38) in a research report on Thursday, April 14th. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Sanofi from €80.00 ($83.33) to €85.00 ($88.54) in a research report on Monday, March 28th. Guggenheim raised their price objective on shares of Sanofi from €121.00 ($126.04) to €127.00 ($132.29) in a research report on Monday, May 2nd. UBS Group raised their price objective on shares of Sanofi from €118.00 ($122.92) to €119.00 ($123.96) and gave the stock a “buy” rating in a research report on Tuesday, June 7th. Finally, Morgan Stanley lifted their price target on shares of Sanofi from €110.00 ($114.58) to €112.00 ($116.67) in a research report on Friday, April 22nd. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $108.83.
Sanofi stock opened at $50.16 on Friday. The stock has a 50-day simple moving average of $52.06 and a 200 day simple moving average of $52.17. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.03 and a current ratio of 1.44. The stock has a market capitalization of $126.77 billion, a P/E ratio of 16.23, a PEG ratio of 1.22 and a beta of 0.50. Sanofi has a 52 week low of $46.92 and a 52 week high of $58.10.
A number of large investors have recently made changes to their positions in the stock. Fieldpoint Private Securities LLC increased its stake in Sanofi by 8.1% in the first quarter. Fieldpoint Private Securities LLC now owns 2,444 shares of the company’s stock valued at $125,000 after acquiring an additional 184 shares during the last quarter. Pinnacle Bancorp Inc. grew its stake in shares of Sanofi by 49.0% during the first quarter. Pinnacle Bancorp Inc. now owns 587 shares of the company’s stock worth $30,000 after buying an additional 193 shares during the last quarter. Keudell Morrison Wealth Management grew its stake in shares of Sanofi by 3.4% during the fourth quarter. Keudell Morrison Wealth Management now owns 5,954 shares of the company’s stock worth $298,000 after buying an additional 198 shares during the last quarter. Dearborn Partners LLC grew its stake in shares of Sanofi by 3.5% during the first quarter. Dearborn Partners LLC now owns 6,115 shares of the company’s stock worth $314,000 after buying an additional 207 shares during the last quarter. Finally, Johnson Financial Group Inc. grew its stake in shares of Sanofi by 20.2% during the fourth quarter. Johnson Financial Group Inc. now owns 1,369 shares of the company’s stock worth $69,000 after buying an additional 230 shares during the last quarter. 12.82% of the stock is currently owned by institutional investors and hedge funds.
The firm also recently declared an annual dividend, which was paid on Wednesday, June 8th. Stockholders of record on Thursday, May 5th were given a $1.7968 dividend. The ex-dividend date was Wednesday, May 4th. This represents a dividend yield of 2.7%. Sanofi’s payout ratio is 40.78%.
Sanofi Company Profile (Get Rating)
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products.
Read More
Receive News & Ratings for Sanofi Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Sanofi and related companies with MarketBeat.com’s FREE daily email newsletter.
Read More: Q4 2022 EPS Estimates for Sanofi Decreased by Analyst (NASDAQ:SNY)